Piper Sandler analyst Joseph Catanzaro assigned a Buy rating to Leap Therapeutics (LPTX – Research Report) today and set a price target of $21.00. The company’s shares opened today at $3.21.
Catanzaro covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Biomea Fusion, and Keros Therapeutics. According to TipRanks, Catanzaro has an average return of 4.0% and a 38.43% success rate on recommended stocks.
Leap Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.75, implying a 297.20% upside from current levels. In a report released on January 16, Mizuho Securities also maintained a Buy rating on the stock with a $12.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $10.20 and a one-year low of $1.24. Currently, Leap Therapeutics has an average volume of 263.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Leap Therapeutics (LPTX) Company Description:
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Read More on LPTX:
